Only 1.8% of all thyroid cancers develop in children or adolescents, but the incidence appears to be increasing. [1] [2] [3] The majority of differentiated thyroid cancers (DTCs) in children are papillary thyroid cancers (PTCs), including the follicular, tall-cell, columnar, diffuse sclerosing, and encapsulated variants. 4 Follicular thyroid cancer (FTC) is less common and includes the subtypes of Hürthle-cell (oncocytic), clear-cell, and insular (poorly differentiated) carcinoma. 4 Medullary thyroid cancer (MTC) is uncommon in this age group and is usually associated with multiple endocrine neoplasia type II. [5][6][7][8] Activation of the RAS-RAF-MEK-ERK (mitogen-activated protein kinase [MAPK]) pathway is a central feature of thyroid cancers and provides the opportunity for targeted therapies beyond surgery or radioactive iodine.
7,11,42 These differences might be important in the lower disease-specific mortality observed in children with DTC.
Thyroid Nodules
Thyroid nodules are uncommon in pre-pubertal children (1-1.5%) but have been reported in a fairly high proportion of adolescents (13%) when examined by ultrasound (US) or post-mortem thyroid sectioning. 31, 43 Preferably under US guidance, fine-needle aspiration (FNA), is increasingly used to determine the benign or malignant nature of thyroid nodules in children. 31, [44] [45] [46] As experience with FNA has increased in children, the probability of false-negative results has declined. A recent meta-analysis by Stevens et al. included 12 papers and found good sensitivity (94%), specificity (81%), and accuracy (83.6%). 47 In children with more than one nodule, selection of the nodule for FNA is often based on US features. 48 While size has not readily distinguished malignant from benign lesions in children, hypoechogenicity, irregular margins, and increased intranodal vascularization are more common among malignant lesions. 48 Molecular signatures to help improve diagnosis by FNA are also being tested but remain experimental.
49-52
Despite these advances, there remains a small probability, perhaps as high as 7%, that a malignant lesion will fail to be correctly identified by US and FNA. 53 Although limited, data suggest that close follow-up and later treatment will be successful for detecting and treating such misdiagnosed lesions. Ito et al. performed a retrospective analysis of 56 patients with PTC who underwent thyroidectomy without lymph-node dissection for a presumptive diagnosis of benign nodule. 54 Only 5.3%
developed recurrent disease and none died from disease, suggesting that cancers that appear benign on FNA and US are likely to follow an indolent course that will probably not have a negative impact on survival when they are identified and treated at a subsequent date. Some, but not all, benign nodules regress spontaneously. 55 Because of that and side effects associated with thyroid-stimulating hormone (TSH) suppression, some clinicians favor TSH suppression while others do not.
31,56-60

Pre-operative Staging of Differentiated Thyroid Cancer in Children
Pre-operative staging is necessary to direct the initial management of children with DTC. At a minimum, pre-operative studies generally include a chest radiograph (CXR) and comprehensive neck US to interrogate the contralateral thyroid lobe and the lymph nodes in the central and lateral compartments. 61 As the majority of children with PTC have cervical node involvement, 8, 12, 14, 15, [33] [34] [35] pre-operative US is paramount to identify those children who will require lymph node dissection at the time of thyroidectomy (see Figure 1 ). To facilitate surgical planning for children with bulky metastatic lymphadenopathy, many surgeons also consider computed tomography (CT) or magnetic resonance imaging (MRI) of the neck. If iodinated contrast agents are used for this procedure, therapeutic RAI will need to be delayed until total body iodine burden returns to normal (generally two to three months).
Nuclear scintigraphy is not included in the pre-operative staging of the child with an intact thyroid and a normal TSH. RAI uptake in the lungs after initial surgical therapy appears to be the most sensitive indicator of pulmonary metastases. 37 For that reason, chest CT is usually obtained only if pulmonary metastatic disease is documented after treatment with RAI. DTCs in children are well-differentiated tumors with robust RAI uptake and there appears to be no benefit from positron emission tomography (PET) scanning for this initial staging. pre-pubertal and pubertal children were similar when both groups were similarly treated. 73 They postulated that previous studies may have shown poor outcomes for pre-pubertal children because they were not To facilitate RAI uptake, a low-iodine diet is generally prescribed for two weeks prior to therapy. In children who received intravenous contrast during pre-operative staging, it is advisable to wait two to three months or confirm normal 24-hour urinary iodine values before performing a diagnostic thyroid scan. There are no standardized doses of RAI for children. Some adjust 131 I dose according to weight or body surface area (BSA) and give a fraction (e.g. child's weight in kg/70kg) based on the typical adult dose used to treat similar disease Thyroid Disorders 
Special Cases in Children
One-third of PTCs in adults are now micro-PTCs (<1cm in diameter) that are detected by imaging for unrelated conditions or after thyroid surgery for another indication. 119 The natural history of these lesions is not well understood, but adults with micro-PTC are commonly managed as low-risk patients. recurrence rates were similar but most patients were treated with total thyroidectomy and RAI. 12 Because angioinvasion and hematogenous spread can occur even without regional lymph node disease, most patients with invasive FTC are treated with total thyroidectomy and RAI. 125 Lymph nodes in more aggressive variants of FTC are managed similarly to PTC.
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The management of minimally invasive FTC is controversial, even in adults, and the optimal management for children is unknown. 126, 127 Many surgeons perform lobectomy alone and consider this sufficient surgery with close follow-up and possible TSH suppression. In a study of 37 patients <45 years of age with minimally invasive FTC, 10-year disease-free survival was 92% and none of the patients developed distant metastases, 126 suggesting that minimally invasive FTC might be less aggressive in young patients.
Thyroid Hormone Suppression and Follow-up
TSH suppression is almost always prescribed for post-operative DTC in children, but the optimal level of suppression is debated. 128 Some have recommended initial suppression of TSH to <0.1µIU/ml followed by relaxation of TSH to 0.5µIU/ml, once children enter remission. 110 Recent American Thyroid Association (ATA) guidelines are also followed by many practitioners. 27 Although unstudied, potential risks of long-term TSH suppression (such as negative effects on growth, cognition, bone mineralization, and the heart) are likely to be minimal in the otherwise-healthy pediatric population. 141 We do not know whether
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Unfortunately, thyroglobulin antibodies (TgAb) are detected in almost 25% of patients with thyroid cancer and interfere with serum Tg assays, rendering the Tg level uninterpretable. 142 For these patients, a decline in TgAb indicates declining disease burden but it takes a median of three years to clear TgAb levels after cure of DTC. 143 A significant rise in TgAbs suggests disease progression and warrants further evaluation. Once the child becomes TgAb-negative, he or she can be followed using routine measurement of the suppressed Tg, and at least one TSH-stimulated
Tg can be assessed to determine serological evidence of disease, assuming the suppressed Tg is negative.
Treatment of Residual/Recurrent Cervical Disease
Recurrent PTC develops in 30% of children and most commonly occurs in cervical lymph nodes. 39 In most cases, cervical disease can be effectively treated with repeat surgery. 144 Surgical complications are more common with re-exploration of the neck but should be minimized when the operation is performed by a high-volume surgeon. Although many patients may be cured after repeat neck surgery, not everyone will develop an undetectable Tg level. 144 Nevertheless, if cervical recurrence can be surgically removed, this is preferred over RAI, which is not particularly effective for macroscopic lymph node disease (see Figure 2 ).
Treatment of Children with Pulmonary Metastases
Up to 20% of children with DTC may have pulmonary metastases at diagnosis. 8,12,15,33,34,36-39 RAI therapy is indicated for patients with iodine-avid pulmonary metastases (see Figure 2 ), but care must be taken to select a dose that will adequately treat metastases yet not result in adverse effects such as pulmonary fibrosis. Care must also be taken not to treat the child too frequently, as death from TNM stage II DTC is unexpected during childhood and also because the response to RAI may continue beyond one year or more. Empiric dosing may not be the best approach for children with diffuse uptake on diagnostic RAI The advent of targeted therapies in the form of oral small-molecule tyrosine kinase inhibitors has revolutionized the management of RAI-refractory DTC. A variety of agents now show promise in the treatment of this once-orphan disease. 10, 151, 152 To date, sorafenib has been the best studied and has shown benefit in treatment-refractory thyroid cancer in phase II clinical trials and a retrospective off-label study. [153] [154] [155] [156] In subjects with differentiated, poorly differentiated and anaplastic thyroid carcinomas, the best response achieved with the use of sorafenib was a partial response in 11-25% and stable disease in 34-63%, giving an overall clinical benefit (partial response plus stable disease) in 59-77% of patients treated. There were no complete responses and up to 23% of subjects, chiefly those with poorly differentiated or frankly anaplastictumors, had progressive disease while taking sorafenib. It also appears that sorafenib may work more effectively for lung metastases compared with lymph node and bony metastatic disease. 155, 156 The only published experience using sorafenib to treat pediatric thyroid cancer has been a single case report. 157 In that case, a 14-year-old girl with iodine non-avid progressive pulmonary metastatic disease demonstrated a partial response to treatment with sorafenib. Other oral tyrosine kinase inhibitors (TKIs) that are showing promise in the treatment of advanced DTC in adults include axitinib, motesanib, pazopanib, and sunitinib. 151, [158] [159] [160] [161] 162 Although much more study is required regarding the use of these agents in children, particularly as it relates to dosing and toxicities, the use of an oral tyrosine kinase inhibitor, particularly sorafenib, may be contemplated in the very rare situation where a child warrants systemic approaches to treatment. 
